Longevica names a new CEO as it pivots toward preclinical drug development; read an update on leadership and strategic direction.
Key Takeaways
- Longevica is shifting from discovery toward IND-enabling preclinical drug development under new executive leadership
- $13 million in vivo screen evaluated 1,033 compounds across more than 16,000 mice
- Guided programs, and strategic biopharma partnerships for clinical translation